FDA proposes reclassifying digital breast tomosynthesis systems from class III to class II
Governed issue brief
Retain as Core. FDA is proposing a material pathway change for digital breast tomosynthesis systems from class III PMA to class II 510(k) with special controls. It remains a proposal: no sponsor should treat reclassification, a clearance route or the proposed effective date as final before the final order.
In a Federal Register proposed order published 10 August 2026, FDA proposed reclassifying digital breast tomosynthesis systems under product code OTE from postamendments class III into class II with special controls and premarket notification. FDA also proposed a new device classification regulation identifying the category and the controls it considers necessary for reasonable assurance of safety and effectiveness. Electronic or written comments are due 9 October 2026; the notice does not itself complete reclassification.
FDA proposes reclassifying digital breast tomosynthesis systems from class III to class II
Implications and action
This proposal can materially change the regulatory pathway, submission architecture and quality evidence expected for a commercially important imaging device category. It is Core because teams need to act now on comment strategy and gap assessment, while keeping the proposal/final boundary explicit. The operational question is not whether controls disappear, but how PMA-level oversight would be replaced by general and special controls under class II.
Regulatory and device-quality owners should assess affected OTE-coded products, map the proposed special controls against current design, clinical, software, labelling and post-market evidence, and submit supported comments by 9 October 2026 where appropriate. Development plans should maintain the current PMA basis until a final order becomes effective, with scenario planning controlled as prospective work.
A final class II pathway could lower time and evidence burdens for some DBT entrants while making compliance with special controls a sharper competitive differentiator. Incumbents and new entrants should model both routes without booking timing or cost benefits before the final order.
FDA proposes reclassifying digital breast tomosynthesis systems from class III to class II
Evidence and reader takeaways
- FDA proposes moving OTE digital breast tomosynthesis systems from class III to class II.
- The proposed route would use premarket notification and device-specific special controls.
- Comments are due by 9 October 2026.
- The notice is not a final reclassification or immediate pathway change.
Primary source: FDA Federal Register document 2026-16209, independently captured official API SHA-256 ce1e040871aa41795ef01c8e6296bc3ab575e1db008600952185c0fe09e39b26. Evidence boundary: proposed order only; comments close 9 October 2026.
DBT, Digital breast tomosynthesis · PMA, Premarket approval · 510(k), Premarket notification
FDA proposes reclassifying digital breast tomosynthesis systems from class III to class II
FDA's proposed DBT reclassification could replace PMA with 510(k) plus special controls, reshaping evidence, design-control and market-entry planning for an established imaging category.
This proposal can materially change the regulatory pathway, submission architecture and quality evidence expected for a commercially important imaging device category. It is Core because teams need to act now on comment strategy and gap assessment, while keeping the proposal/final boundary explicit. The operational question is not whether controls disappear, but how PMA-level oversight would be replaced by general and special controls under class II.
Regulatory and device-quality owners should assess affected OTE-coded products, map the proposed special controls against current design, clinical, software, labelling and post-market evidence, and submit supported comments by 9 October 2026 where appropriate. Development plans should maintain the current PMA basis until a final order becomes effective, with scenario planning controlled as prospective work.